marketwatch
: NeuroSense Therapeutics started at buy with $7.50 stock price target at Alliance Global Partners
MarketWatch • 2 YEARS AGO
: BridgeBio Pharma announces positive results in late-stage trial of treatment for ATTR-CM
MarketWatch • 2 YEARS AGO
: Mallinckrodt still has not determined whether it will file for bankruptcy
MarketWatch • 2 YEARS AGO
